Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

660.09 -3.00 (-0.45%)
Streaming Delayed Price Updated: 1:41 PM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday. 
Via Chartmill
News headline image
Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Here Are the Top Growth Healthcare Stocks Every New Investor Should Know ↗
These top growth stocks have plenty of room left to run. 
Via The Motley Fool
News headline image
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗
CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform. 
Via Benzinga
News headline image
Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at immuno-oncology stocks, starting with... 
Via StockStory
Topics Artificial Intelligence
News headline image
Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks
Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗
Merck said Saturday its new pill — a possible rival to Regeneron and Amgen — lowered high cholesterol by almost 60%. 
Via Investor's Business Daily
News headline image
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest ↗
 
Via Benzinga
News headline image
The Shadow of Doubt: Why Investors Are 'Taking Fright' as Markets Brace for Reality
In the dynamic world of finance, where fortunes are made and lost in the blink of an eye, a chilling sentiment has begun to grip investors: the idea that stocks can, indeed, go down. This isn't merely... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call
Regeneron’s third quarter results were well received by the market, reflecting strong execution in its commercial portfolio and key products. Management attributed the positive momentum to double-digit... 
Via StockStory
Topics Earnings
News headline image
Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts ↗
Michael Burry's Scion Asset Management filed an updated 13F showing a new large bearish position in Palantir and Nvidia, among others. 
Via Benzinga
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Beaten-Down Stocks That Could Be About to Rally ↗
It would be best to get in before the rest of the market pounces on these opportunities. 
Via The Motley Fool
News headline image
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage
Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per... 
Via StockStory
News headline image
Regeneron (REGN) Q3 2025 Earnings Call Transcript ↗
Regeneron (REGN) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday? ↗
Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech earnings. 
Via Benzinga
Topics Economy
News headline image
Why Are Regeneron (REGN) Shares Soaring Today
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported third-quarter financial results that surpassed analyst expectations for both revenue and profit. 
Via StockStory
Topics Artificial Intelligence
News headline image
These S&P500 stocks are gapping in today's session ↗
Let's have a look at the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
These S&P500 stocks that are showing activity before the opening bell on Tuesday. ↗
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness ↗
Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales. 
Via Benzinga
News headline image
Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts ↗
Regeneron stock advanced early Tuesday on better-than-expected third-quarter earnings despite a big tax hit. 
Via Investor's Business Daily
News headline image
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2025 Earnings Beat Estimates ↗
Regeneron (REGN) Q3 2025 earnings beat estimates with $11.83 EPS on $3.75B revenue. Strong performance driven by Dupixent and Libtayo sales growth. 
Via Chartmill
Topics Earnings
News headline image
Regeneron (NASDAQ:REGN) Surprises With Strong Q3
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per share was... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.